MINAPHARM Pharmaceuticals (EGX:MIPH)
Egypt · Delayed Price · Currency is EGP 663.03
+2.37 (0.36%)
At close: Jun 24, 2026
MINAPHARM Pharmaceuticals Cash Flow Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 40.22 | 157.07 | -31.99 | 612.66 | 466.41 |
Depreciation & Amortization | 380.18 | 284.71 | 192.23 | 132.86 | 85.99 |
Loss (Gain) From Sale of Assets | 0.15 | 5.67 | 0.17 | - | -0.46 |
Provision & Write-off of Bad Debts | 20 | 40 | 12.64 | -2.67 | -8.91 |
Other Operating Activities | 18.86 | 158.86 | -88.92 | 81.64 | 90.93 |
Change in Accounts Receivable | 279.66 | -271.35 | -147.28 | -168.51 | -22.41 |
Change in Inventory | -277.91 | -180.96 | -226.43 | -171.08 | -83.29 |
Change in Accounts Payable | -58.45 | 265.8 | 39.82 | 265.15 | -91.57 |
Change in Other Net Operating Assets | 62.11 | -238.28 | 352.1 | -188.28 | -229.4 |
Operating Cash Flow | 464.81 | 221.51 | 102.34 | 561.77 | 207.28 |
Operating Cash Flow Growth | 109.83% | 116.44% | -81.78% | 171.03% | -52.58% |
Capital Expenditures | -787.8 | -918.96 | -1,395 | -1,160 | -387.87 |
Sale of Property, Plant & Equipment | - | - | 0.17 | - | 0.76 |
Sale (Purchase) of Intangibles | -3.94 | -0.09 | -10.65 | -2.03 | -1.82 |
Other Investing Activities | 63.88 | 45.26 | 0 | 0 | -0.01 |
Investing Cash Flow | -727.85 | -573.79 | -1,405 | -1,162 | -388.94 |
Short-Term Debt Issued | 5,962 | 2,496 | 1,020 | 494.8 | - |
Long-Term Debt Issued | 909.35 | 1,334 | 459.34 | 636.62 | 425.73 |
Total Debt Issued | 6,871 | 3,830 | 1,479 | 1,131 | 425.73 |
Short-Term Debt Repaid | -6,388 | -2,227 | - | - | -205.3 |
Long-Term Debt Repaid | -1,870 | -292.72 | -128.71 | -12.15 | -11.86 |
Total Debt Repaid | -8,258 | -2,520 | -128.71 | -12.15 | -217.16 |
Net Debt Issued (Repaid) | -1,386 | 1,310 | 1,350 | 1,119 | 208.57 |
Issuance of Common Stock | 2,173 | - | - | - | - |
Repurchase of Common Stock | - | - | - | -69.63 | - |
Common Dividends Paid | -60.31 | -40.16 | -53.87 | -57.79 | -49.8 |
Other Financing Activities | -27.47 | 46.35 | -0.08 | 2.31 | -3.2 |
Financing Cash Flow | 699.34 | 1,316 | 1,296 | 994.16 | 155.57 |
Foreign Exchange Rate Adjustments | 33.06 | 5.49 | 230.86 | 317.88 | -13.97 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | -1.5 |
Net Cash Flow | 469.35 | 969.43 | 224.34 | 711.56 | -41.56 |
Free Cash Flow | -322.99 | -697.45 | -1,292 | -598.45 | -180.6 |
Free Cash Flow Margin | -5.02% | -12.46% | -33.21% | -16.53% | -6.01% |
Free Cash Flow Per Share | -29.19 | -63.04 | -116.81 | -52.16 | -14.69 |
Cash Interest Paid | 748.64 | 593.68 | 254.46 | 62.17 | 48.84 |
Cash Income Tax Paid | 76.84 | 26.07 | 132.95 | 182.39 | 154.77 |
Levered Free Cash Flow | -183.62 | -362.97 | -1,317 | -622.61 | -139.42 |
Unlevered Free Cash Flow | 284.28 | 8.07 | -1,158 | -583.75 | -108.9 |
Change in Working Capital | 5.4 | -424.79 | 18.21 | -262.72 | -426.67 |